Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Choosing the right accounts—taxable, tax-advantaged, or retirement—can significantly reduce taxes on index fund gains and distributions.
25,988 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
February market action favors growth names as earnings beat and cash flow strengthens. This report highlights three h...
Axon Enterprise jumped in premarket trading following a strong Q4 and a sharp rise in annual bookings, signaling dura...
Rocket Companies closed 2025 with $6.7 billion in revenue and rising mortgage activity, alongside strategic deals tha...
Nvidia sits at the heart of AI infrastructure, but its stock faces a potential shift this March. This guide breaks do...
A noted tech investor forecasts AI could automate most jobs by 2030. This report explores how families might keep ess...
Serve Robotics beats Q4 revenue estimates, lifts 2026 guidance to roughly 10x 2025 levels, and gains credibility from...
A focused look at OmniAb's Q4 2025 earnings and what the numbers could mean for investors. Discover the drivers, risk...
Mosaic’s rare earths could become a new growth engine as the company partners with Rainbow Rare Earths to recover NdP...
Tim Cook used the China Development Forum to stress collaboration with Chinese partners as Beijing intensifies policy...
EQT Corp is becoming a cash machine, with free cash flow rising and margins expanding. Wall Street is warming to the ...
Ethereum failed to push above the $2.4K threshold, leaving the asset trapped in a tightening range as traders weigh d...